5.96 USD
-0.23
3.72%
At close May 14, 4:00 PM EDT
After hours
6.01
+0.05
0.84%
1 day
-3.72%
5 days
-17.11%
1 month
-7.02%
3 months
-27.23%
6 months
-17.45%
Year to date
-30.46%
1 year
-55.79%
5 years
-84.44%
10 years
-96.55%
 

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Employees: 1,992

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

44% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 54

5.49% more ownership

Funds ownership: 58.55% [Q3] → 64.04% (+5.49%) [Q4]

5% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 41

3% less funds holding

Funds holding: 233 [Q3] → 226 (-7) [Q4]

29% less call options, than puts

Call options by funds: $65.9M | Put options by funds: $92.9M

30% less capital invested

Capital invested by funds: $1.19B [Q3] → $825M (-$361M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
17%
upside
Avg. target
$7
17%
upside
High target
$7
17%
upside

1 analyst rating

positive
0%
neutral
0%
negative
100%
JP Morgan
Eric Joseph
41% 1-year accuracy
12 / 29 met price target
17%upside
$7
Underweight
Maintained
9 May 2025

Financial journalist opinion

Based on 29 articles about NVAX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Positive
Seeking Alpha
2 days ago
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven by $603M from terminated APA agreements and $19M from new vaccine shipments, indicating strong demand. Sanofi partnership converts lower-margin product revenue to higher-margin income, allowing Novavax to focus on R&D and achieve non-GAAP profitability by 2027.
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Positive
Zacks Investment Research
5 days ago
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
5 days ago
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Positive
Benzinga
6 days ago
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Neutral
Seeking Alpha
6 days ago
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Tom Shrader - BTIG Eric Joseph - JPMorgan Chris LoBianco - TD Securities Operator Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call.
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Neutral
Barrons
6 days ago
Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
Novavax has seen its shares plummet since the pandemic because of weakening demand.
Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
Positive
Zacks Investment Research
6 days ago
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago.
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Positive
Reuters
6 days ago
Novavax swings to profit on lower expenses related to COVID shots
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.
Novavax swings to profit on lower expenses related to COVID shots
Neutral
PRNewsWire
6 days ago
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on average Data presented at World Vaccine Congress showcases Matrix-M ® utility when co-administered with a broad array of vaccine platforms and diseases Strengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial terms Raises full year 2025 revenue framework to between $975 million and $1,025 million Reiterates full year 2025 financial guidance for combined R&D and SG&A expenses of between $475 million and $525 million Recorded total revenue of $667 million in the first quarter of 2025 C ompany to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
Charts implemented using Lightweight Charts™